Critical Care
Our hospital portfolio focuses on the following therapeutic areas: Haemmorhage, epilpsy and infectious diseases.
We rethink
generics
Towards More Efficient Healthcare
Stragen Nordic A/S now has a large portfolio of products in the antibiotic, haemorhage, epilepsy and oral contraceptive markets.
R&D
Our specialized and dedicated scientific team works continuously according to the latest quality standards to provide tailored solutions to our partners.
Committed to patient well-being and treatment adherence, Stragen Laboratory initiates research projects focused on fundamental criteria, namely:
- Innovation through new formulations to enhance the tolerance of our products.
- Development of new stability data to improve the use of our products.
- Introduction of new dosage forms to facilitate the use of our products, especially in emergency situations.
- Launch of new packaging and dosages to diversify our propositions and satisfy the needs and expectations of our partners more proficiently.